Lilly and UK government announce £279 million collaboration to tackle population health challenges including obesity
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
WHO issues warning on falsified medicines as Lilly warns patients about counterfeit and compounded medicines
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity
Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks
SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight
